Congenital Heart Disease (CHD), known locally in Indonesia as Penyakit Jantung Bawaan (PJB), remains one of the most significant challenges in neonatal and pediatric medicine, representing a complex array of structural abnormalities that occur during the early stages of fetal development. While the precise etiology of many heart defects remains elusive to the medical community, healthcare experts are increasingly focusing on identifiable risk factors that can be managed or avoided during pregnancy to reduce the incidence of these life-threatening conditions. Dr. Rizky Adriansyah, a pediatric specialist and Chairman of the Cardiology Coordination Unit of the Indonesian Pediatric Society (IDAI), recently emphasized that while a direct cause-and-effect relationship is difficult to establish in every case, several critical environmental and biological factors significantly elevate the risk of a child being born with a heart defect.
The complexity of CHD lies in its developmental timeline, as the human heart begins to form and beat as early as three to eight weeks into gestation—often before a woman even realizes she is pregnant. During this critical window, any disruption to the intricate biological signaling required to form chambers, valves, and arteries can lead to permanent structural issues. According to Dr. Rizky, speaking during a comprehensive webinar on February 14, 2023, the medical community has identified three primary risk factors that have gained significant attention in recent clinical literature: maternal infections such as Rubella, nutritional deficiencies specifically involving folic acid, and the consumption of certain high-risk medications, such as anti-seizure drugs, during pregnancy.
The Triad of Avoidable Risk Factors
The first and perhaps most preventable risk factor is the Rubella virus, also known as German measles. When a pregnant woman contracts Rubella, the virus can cross the placental barrier, leading to Congenital Rubella Syndrome (CRS). This syndrome is notorious for causing a triad of complications: deafness, cataracts, and serious congenital heart defects, most commonly patent ductus arteriosus (PDA) and pulmonary artery stenosis. Dr. Rizky underscored the importance of the Rubella vaccine as a primary preventive measure. Ensuring that women of childbearing age are immunized before conception creates a protective shield that virtually eliminates this specific risk pathway.
The second major factor involves maternal nutrition, specifically the intake of folic acid (Vitamin B9). Folic acid plays a quintessential role in DNA synthesis and repair, as well as in the rapid cell division that characterizes fetal growth. While its role in preventing neural tube defects like spina bifida is well-documented, emerging research and clinical consensus now strongly link adequate folic acid levels to healthy cardiac development. A deficiency during the first trimester can result in septal defects, commonly referred to as "holes in the heart." Consequently, medical professionals urge expectant mothers to consume folic acid-rich foods—such as leafy greens, legumes, and fortified cereals—and to adhere to supplementation protocols prescribed by their obstetricians.
The third pillar of risk involves the use of teratogenic medications. Dr. Rizky highlighted that certain drugs used to treat chronic conditions, such as epilepsy or seizure disorders, can interfere with fetal heart formation. This presents a complex challenge for maternal health, as the mother’s underlying condition must be managed while minimizing risk to the fetus. It is essential for women with pre-existing conditions to consult with their physicians before and during pregnancy to adjust dosages or switch to safer alternatives. Additionally, historical data has long pointed to the consumption of alcohol and tobacco as significant risk factors. While many cases of CHD occur in children whose mothers did not smoke or drink, the statistical correlation remains strong enough that total abstinence is the only recommended course of action.
Statistical Realities and the Indonesian Context
The impact of CHD on public health in Indonesia is profound. National data from 2017 indicates that CHD is the second leading cause of neonatal mortality, accounting for approximately 17 percent of deaths in the first month of life, trailing only prematurity. This statistic highlights a critical gap in the country’s ability to manage neonatal emergencies. On a global scale, the World Health Organization (WHO) estimates that one in every 100 newborns suffers from some form of CHD. Of these cases, approximately 25 percent are classified as "critical CHD," meaning the infant will require surgical intervention or catheterization within the first year—and often the first month—of life to survive.
In Indonesia, the discrepancy between the number of births and the number of successfully treated CHD cases is a matter of grave concern. Dr. Rizky noted that currently, less than 50 percent of CHD cases in the country receive the necessary medical or surgical intervention. This "treatment gap" is the result of a multifaceted crisis involving geography, infrastructure, and human resources. As an archipelago, Indonesia faces immense logistical hurdles in transporting critically ill newborns from remote islands to specialized cardiac centers, which are predominantly located in major urban hubs like Jakarta, Surabaya, and Bandung.
Furthermore, there is a severe shortage of pediatric cardiologists and cardiovascular surgeons specialized in neonates. The specialized equipment required for diagnosis, such as advanced echocardiography machines, is not universally available in all regional hospitals. Beyond infrastructure, there is also the issue of public awareness; many parents do not recognize the subtle early signs of heart distress, leading to late-stage diagnoses where the window for successful intervention has narrowed significantly.
Advancements in Early Detection and Diagnosis
To combat the high mortality rate, the medical community is advocating for more aggressive and accessible screening methods. One of the most effective and cost-efficient tools available is pulse oximetry. This non-invasive test measures the oxygen saturation in a baby’s blood and is highly sensitive in detecting critical CHD before the infant shows obvious symptoms of distress. The procedure involves placing a small sensor on the baby’s right hand and either of the feet. A significant difference in oxygen levels between the upper and lower extremities, or a low overall saturation level, serves as a "red flag" for potential heart defects.
Dr. Rizky emphasized that this screening is fast, inexpensive, and can be performed by midwives or general practitioners in less than five minutes. Given that many births in Indonesia occur in primary care settings or at home with the assistance of midwives, empowering these frontline workers to use pulse oximeters could revolutionize early detection.
In addition to oximetry, the traditional stethoscope remains a vital tool. The presence of a heart "murmur"—an unusual sound heard between heartbeats—often warrants an immediate referral to a specialist for an echocardiogram. An echocardiogram uses ultrasound waves to create a live image of the heart’s structure and function, allowing doctors to pinpoint exactly where the defect lies. For critical cases, these symptoms often manifest within the first 24 to 48 hours of life, or at the latest, within the first week.
Clinical Symptoms and Parental Vigilance
Parents play a crucial role in the early detection of CHD, especially for non-critical cases that may not be immediately apparent at birth. One of the primary clinical signs of a heart defect in infants is poor weight gain or "failure to thrive." Because the heart has to work significantly harder to pump blood to the body, the infant burns more calories than they can consume. These babies may also exhibit excessive sweating during feeding, rapid breathing, or a bluish tint to the lips and fingernails (cyanosis).
To bridge the information gap, Dr. Rizky and various health organizations have turned to digital platforms for education. The YouTube channel "Sehatkan Jantung Anak Indonesia" (Healthy Indonesian Children’s Hearts) serves as a vital resource for both parents and healthcare workers, providing visual guides on how to perform screenings and what symptoms to watch for. This democratization of medical knowledge is essential in a country where access to specialists is limited.
Analysis of Implications and the Path Forward
The implications of failing to address the CHD crisis in Indonesia are both humanitarian and economic. Each untreated case represents a lost potential and a significant emotional burden on families. From an economic perspective, the cost of late-stage emergency interventions and the long-term care of children with chronic heart failure far exceeds the cost of early screening and timely surgical correction.
To improve outcomes, a systemic shift is required. First, the Indonesian government must prioritize the integration of critical CHD screening into the standard newborn care package nationwide. This includes ensuring that every birthing facility, no matter how remote, is equipped with a functional pulse oximeter. Second, there must be a concerted effort to increase the number of pediatric cardiac specialists through scholarships and enhanced training programs.
Furthermore, the "referral pathway" needs optimization. When a midwife in a remote province detects a potential heart defect, there must be a clear, rapid protocol for getting that child to a tertiary care center. This may involve the expansion of regional cardiac hubs so that life-saving surgery is not a thousand miles away.
The words of Dr. Rizky Adriansyah serve as both a warning and a call to action. While the "cause" of congenital heart disease might remain a mystery of biology, the "risk" is something that can be managed through better maternal health, and the "outcome" is something that can be changed through early detection. The goal is clear: to ensure that every child born in Indonesia, regardless of their place of birth, has a fair chance at a healthy heart and a full life. Through a combination of maternal education, frontline healthcare empowerment, and structural investment, the 17 percent neonatal mortality rate attributed to CHD can—and must—be reduced.
